PALI
USDPalisade Bio Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$1.910
Haut
$1.970
Bas
$1.822
Volume
1.22M
Fondamentaux de l'Entreprise
Capitalisation Boursière
259.3M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
8.45M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA,
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients
Actions Connexes
WDI
Western Asset Diversified Income Fund Common Shares of Beneficial Interest
TRGP
Targa Resources Inc.
DECK
Deckers Outdoor Corporation
CMSC
CMS Energy Corporation 5.875% Junior Subordinated Notes due 2078
ENTO
Entero Therapeutics Inc.
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.